BR0208676A - anticorpo monoclonal quimérico, linhagem celular, composição farmacêutica, e, uso de um anticorpo monoclonal - Google Patents

anticorpo monoclonal quimérico, linhagem celular, composição farmacêutica, e, uso de um anticorpo monoclonal

Info

Publication number
BR0208676A
BR0208676A BRPI0208676-0A BR0208676A BR0208676A BR 0208676 A BR0208676 A BR 0208676A BR 0208676 A BR0208676 A BR 0208676A BR 0208676 A BR0208676 A BR 0208676A
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
antibodies
murine
pharmaceutical composition
frs
Prior art date
Application number
BRPI0208676-0A
Other languages
English (en)
Other versions
BR0208676B1 (pt
Inventor
Cristina M Mateo De Acosta Rio
Josefa Lombardero Valladares
Lourdes Tatiana Roque Navarro
Alejandro Lopez Requena
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of BR0208676A publication Critical patent/BR0208676A/pt
Publication of BR0208676B1 publication Critical patent/BR0208676B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTICORPO MONOCLONAL QUIMéRICO, LINHAGEM CELULAR, COMPOSIçãO FARMACêUTICA, E, USO DE UM ANTICORPO MONOCLONAL A presente invenção refere-se à obtenção de anticorpos modificados por engenharia genética a partir do anticorpo monoclonal murino P3 (AcM P3), produzido pelo hibridoma depositado segundo o tratado de Budapeste sob o número ECACC 94113026 e de seu anti-idiotipo 1E10 (AcMai 1E10) produzido pelo hibridoma ECACC 97112901, com o objetivo de se obterem anticorpos com as mesmas propriedades de reconhecimento dos originais mas que sejam menos imunógenos que estes. Os anticorpos quiméricos, contem os domínios variáveis da imunoglobulina murina e as regiões constantes da imunoglobulina humana; e os humanizados, além de conterem as regiões constantes da imunoglobulina humana, estão modificados na região das estruturas (FRs) murinas e em particular naquelas zonas que podem resultar em um sítio antigênico para as células 1, acarretando que algumas posições das FRS são humanizadas. Estes anticorpos podem ser utilizados em diagnóstico e em terapia de diferentes tipos de tumores.
BRPI0208676A 2001-04-06 2002-04-08 Chemical monoclonal antibody, pharmaceutical composition, and, use of a monoclonal antibody BR0208676B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PCT/CU2002/000003 WO2002081496A2 (es) 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores

Publications (2)

Publication Number Publication Date
BR0208676A true BR0208676A (pt) 2008-04-08
BR0208676B1 BR0208676B1 (pt) 2017-11-14

Family

ID=40291118

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0208676A BR0208676B1 (pt) 2001-04-06 2002-04-08 Chemical monoclonal antibody, pharmaceutical composition, and, use of a monoclonal antibody
BRPI0208675-1A BRPI0208675B1 (pt) 2001-04-06 2002-04-08 Combinação imunoterapêutica para a imunoterapia de tumores que superexpressam gangliosídeos, uso da mesma, e, uso de um método para controlar o crescimento e/ou a proliferação de tumores que superexpressam gangliosídeos
BR0208675-1A BR0208675A (pt) 2001-04-06 2002-04-08 Combinação imunoterapêutica para a imunoterapaia de tumores que superexpressam gangliosìdeos, uso da mesma e método para controlar o crescimento e/ou a proliferação de células tumorais que superexpressam gangliosìdeos

Family Applications After (2)

Application Number Title Priority Date Filing Date
BRPI0208675-1A BRPI0208675B1 (pt) 2001-04-06 2002-04-08 Combinação imunoterapêutica para a imunoterapia de tumores que superexpressam gangliosídeos, uso da mesma, e, uso de um método para controlar o crescimento e/ou a proliferação de tumores que superexpressam gangliosídeos
BR0208675-1A BR0208675A (pt) 2001-04-06 2002-04-08 Combinação imunoterapêutica para a imunoterapaia de tumores que superexpressam gangliosìdeos, uso da mesma e método para controlar o crescimento e/ou a proliferação de células tumorais que superexpressam gangliosìdeos

Country Status (37)

Country Link
US (3) US20040253233A1 (pt)
EP (3) EP1798243B1 (pt)
JP (2) JP4366080B2 (pt)
KR (3) KR100863509B1 (pt)
CN (3) CN101054417B (pt)
AR (2) AR033123A1 (pt)
AT (3) ATE378356T1 (pt)
AU (3) AU2002308348B2 (pt)
BG (2) BG66293B1 (pt)
BR (3) BR0208676B1 (pt)
CA (2) CA2441845C (pt)
CU (1) CU23007A1 (pt)
CZ (2) CZ296276B6 (pt)
DE (2) DE60228561D1 (pt)
DK (2) DK1411064T3 (pt)
EA (2) EA006936B1 (pt)
EC (2) ECSP034788A (pt)
ES (2) ES2296986T3 (pt)
HK (3) HK1066818A1 (pt)
HR (2) HRP20030806B1 (pt)
HU (2) HU228106B1 (pt)
IL (2) IL158246A0 (pt)
IS (2) IS2701B (pt)
MX (2) MXPA03008738A (pt)
MY (3) MY137078A (pt)
NO (2) NO331533B1 (pt)
NZ (2) NZ528599A (pt)
PE (1) PE20020972A1 (pt)
PL (2) PL208109B1 (pt)
PT (2) PT1411064E (pt)
SG (1) SG161737A1 (pt)
SI (2) SI1411064T1 (pt)
SK (2) SK287783B6 (pt)
UA (3) UA75393C2 (pt)
UY (2) UY27243A1 (pt)
WO (2) WO2002081661A2 (pt)
ZA (2) ZA200307585B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2006209951B2 (en) * 2005-02-04 2011-04-14 Survac Aps Survivin peptide vaccine
FI20055398A0 (fi) * 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
BRPI0614366A2 (pt) * 2005-08-11 2009-10-06 Arpi Matossian Rogers peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos
PT2407486T (pt) 2005-08-19 2018-02-21 Univ Pennsylvania Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
JP5465542B2 (ja) * 2008-02-22 2014-04-09 片山化学工業株式会社 合成糖脂質含有リポソーム
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
EP2473530B1 (en) * 2009-09-03 2015-04-22 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US9469685B2 (en) * 2011-01-10 2016-10-18 Emory University Antibodies directed against influenza
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
SA113340642B1 (ar) 2012-06-15 2015-09-15 فايزر إنك أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
CN110156893B (zh) 2013-12-17 2023-03-03 基因泰克公司 抗cd3抗体及使用方法
BR112016020009A2 (pt) * 2014-04-10 2017-10-17 Obi Pharma Inc anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
AR105026A1 (es) 2015-06-16 2017-08-30 Genentech Inc ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
ES2144440T3 (es) * 1992-08-18 2000-06-16 Centro Inmunologia Molecular Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CA2137638C (en) * 1993-12-09 1999-07-20 Ana M. V. Lopez Anti gangliosides monoclonal antibodies and their use in the specific active immunotherapy of malignant tumors
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
DK1411064T3 (da) 2008-03-25
KR20080080680A (ko) 2008-09-04
US20040253233A1 (en) 2004-12-16
BG66293B1 (en) 2013-02-28
AR033122A1 (es) 2003-12-03
CN1535282A (zh) 2004-10-06
CA2441845C (en) 2011-06-07
UA86768C2 (ru) 2009-05-25
IS6964A (is) 2003-09-23
KR20030092048A (ko) 2003-12-03
AU2002308348B2 (en) 2007-11-22
KR100863509B1 (ko) 2008-10-15
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
DK1384726T3 (da) 2008-12-15
NO20034436L (no) 2003-12-02
EP1411064B1 (en) 2007-11-14
BG108228A (bg) 2005-04-30
HRP20030806A2 (en) 2005-08-31
CA2443372C (en) 2013-05-28
PT1411064E (pt) 2008-02-12
EP1411064A2 (en) 2004-04-21
PL371770A1 (en) 2005-06-27
US20050069535A1 (en) 2005-03-31
AR033123A1 (es) 2003-12-03
ATE477279T1 (de) 2010-08-15
PL371937A1 (en) 2005-07-11
HUP0401695A3 (en) 2012-05-29
IL158246A (en) 2010-05-31
CN101054417A (zh) 2007-10-17
BG66304B1 (bg) 2013-03-29
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
CA2443372A1 (en) 2002-10-17
KR100946168B1 (ko) 2010-03-11
ES2296986T3 (es) 2008-05-01
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
NZ528598A (en) 2005-03-24
PE20020972A1 (es) 2003-01-02
UY27242A1 (es) 2002-07-31
HUP0401695A2 (en) 2006-08-28
UY27243A1 (es) 2002-09-30
ATE406386T1 (de) 2008-09-15
AU2007231687B2 (en) 2010-09-30
EA006936B1 (ru) 2006-06-30
EA006310B1 (ru) 2005-10-27
BRPI0208675B1 (pt) 2018-03-13
SK287914B6 (sk) 2012-03-02
DE60223547D1 (de) 2007-12-27
CN100349920C (zh) 2007-11-21
MY157372A (en) 2016-06-15
HRP20030805A2 (en) 2005-08-31
MXPA03008739A (es) 2003-12-11
CA2441845A1 (en) 2002-10-17
WO2002081661A3 (es) 2003-01-03
HK1070080A1 (en) 2005-06-10
NO331533B1 (no) 2012-01-23
SK12162003A3 (sk) 2004-05-04
ES2312610T3 (es) 2009-03-01
EA200301098A1 (ru) 2004-04-29
BG108227A (bg) 2005-04-30
JP4366080B2 (ja) 2009-11-18
DE60228561D1 (de) 2008-10-09
HUP0401355A3 (en) 2012-05-29
JP2004528033A (ja) 2004-09-16
HK1066818A1 (pt) 2005-04-01
ECSP034787A (es) 2004-01-28
KR100919617B1 (ko) 2009-09-29
EP1798243A3 (en) 2007-10-17
SG161737A1 (en) 2010-06-29
HRP20030806B1 (en) 2011-11-30
NZ528599A (en) 2005-03-24
NO20034437D0 (no) 2003-10-03
EP1798243B1 (en) 2010-08-11
IL158246A0 (en) 2004-05-12
SI1384726T1 (sl) 2009-04-30
HU228106B1 (en) 2012-11-28
CN101054417B (zh) 2012-07-11
ECSP034788A (es) 2004-01-28
AU2002308347B2 (en) 2006-09-14
AU2007231687A1 (en) 2007-11-22
HU228105B1 (en) 2012-11-28
EA200301097A1 (ru) 2004-02-26
CZ296276B6 (cs) 2006-02-15
DE60223547T2 (de) 2008-09-18
UA75393C2 (en) 2006-04-17
EP1384726A2 (en) 2004-01-28
SK287783B6 (sk) 2011-09-05
BR0208675A (pt) 2004-08-03
ZA200307585B (en) 2004-09-16
IS2701B (is) 2010-11-15
CZ20032641A3 (cs) 2004-07-14
US8758753B2 (en) 2014-06-24
EP1798243A2 (en) 2007-06-20
HRP20030805B1 (en) 2011-11-30
US20100297008A1 (en) 2010-11-25
JP2004525953A (ja) 2004-08-26
SI1411064T1 (sl) 2008-04-30
BR0208676B1 (pt) 2017-11-14
WO2002081496A3 (es) 2004-02-19
WO2002081496A2 (es) 2002-10-17
IS6965A (is) 2003-09-23
ATE378356T1 (de) 2007-11-15
HK1109160A1 (en) 2008-05-30
CU23007A1 (es) 2004-12-17
MY145703A (en) 2012-03-30
PT1384726E (pt) 2008-12-05
MY137078A (en) 2008-12-31
ZA200307679B (en) 2005-03-30
CZ304424B6 (cs) 2014-04-30
CZ20032668A3 (cs) 2004-07-14
CN1507452A (zh) 2004-06-23
NO20034437L (no) 2003-12-02
CN1319991C (zh) 2007-06-06
HUP0401355A2 (hu) 2004-10-28
EP1384726B1 (en) 2008-08-27
MXPA03008738A (es) 2003-12-11

Similar Documents

Publication Publication Date Title
BR0208676A (pt) anticorpo monoclonal quimérico, linhagem celular, composição farmacêutica, e, uso de um anticorpo monoclonal
DE3856108T2 (de) Monoklonale antikörper der zweiten generation mit bindungsspezifität für tag-72 und menschliche karzinome sowie methoden zu ihrer anwendung
Schultes et al. Anti-idiotype induction therapy: Anti-CA125 antibodies (Ab 3) mediated tumor killing in patients treated with Ovarex mAb B43. 13 (Ab 1)
RU96115107A (ru) "очеловеченные" антитела и их использование
Brenner et al. Monoclonal antibodies to human lung tumor antigens demonstrated by immunofluorescence and immunoprecipitation
ATE13692T1 (de) Hybridzellinie zur herstellung komplementfixierender monoklonaler antikoerper gegen menschliche suppressor-t-zellen; antikoerper und verfahren zu seiner herstellung; diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen.
DK40885D0 (da) Monoklonalt antistof, fremgangsmaade og celle til fremstilling deraf,fremgangsmaade til fremstilling af cellen og farmaceutisk praeparat indeholdende det monoklonale antistof
KR900013986A (ko) 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도
JPH05500600A (ja) スフィンゴ糖脂質に対する免疫応答を誘導する抗イディオタイプ抗体及びその使用
PT90582A (pt) Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen
Ezzatifar et al. Large scale generation and characterization of anti-human IgA monoclonal antibody in ascitic fluid of BALB/c mice
DE68922806D1 (de) Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden-trägerkonjugaten.
EP0200464B1 (en) A tumor associated antigen
DE68924983T2 (de) Anti-idiotyp antikörper induktion eines antitumorenresponses.
Maleki et al. Generation and characterization of anti-CD34 monoclonal antibodies that react with hematopoietic stem cells
Collins et al. Monoclonal antibodies to glial fibrillary acidic protein: I. Characterization
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
KR930019820A (ko) 모노클로날 항-강글리오사이드 항체, 이의 제조방법 및 종양 치료제로서의 용도
Kusakabe et al. Accumulation enhancement of human monoclonal antibody HB4C5 to lung tumor xenografts by N-deglycosylation
CR7091A (es) Anticuerpos recombinantes asociados a gangliosidos, su uso en el diagnóstico y tratameinto de tumores
Majidi et al. Production and characterization of monoclonal antibodies against human IgG in Balb/c mouse
JP3112463B2 (ja) モノクローナル抗体の作製方法
KR950704478A (ko) 비(b)형 간염 표면 항원에 대해 활성적인 인체 단일클론 항체의 제조방법(production of human monoclonal antibodies active against hepatitis b surface antigen)
EP0161404B1 (de) Verfahren zur Herstellung von künstlichen biomimetischen Haptenen bzw. Antigenen
Barral et al. Cell–cell adherence as a selection method for the generation of anti-melanoma monoclonal antibodies

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2509 DE 05-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.